News

The mission of the partnership is to advance knowledge in the field of proliferative and degenerative diseases through fundamental and applied biology research. The Ipsen Life Sciences Program

The agreement spans for two years and involves manufacturing of CellaVision’s analysis instruments of a worth of around SEK25 million annually. The new agreement will replace the previous

The patent will serve to enhance protection of the intellectual property underlying the company’s Prometa treatment program. This patent, the second allowance in the US, represents the securing

Curacyte’s hemoximer (Pyridoxalated Hemoglobin Polyoxyethylene, PHP) has been developed as a scavenger of nitric oxide, the main causative agent responsible for vasodilation and hypotension in shock. Hemoximer has

Under terms of this agreement, Inverness Medical Innovations will have semi-exclusive global rights to commercialize products using the BioCurex-discovered RECAF blood tests for cancer detection. BioCurex will be

The company will continue to utilize PDI’s Select Access team for an additional two seasons to reach primary care physicians and will be exclusive to pediatric targets. This

Since the recent introduction of a negative pressure device by Innovative Therapies (ITI), Kinetic Concepts (KCI) has discovered that the device unlawfully incorporates inventions covered by the three

Q-Med will eventually be responsible for the marketing, advertising, promotion, sale and distribution of Palomar’s professional products for aesthetic treatments outside North America. In addition, Palomar and Q-Med

Mr. Tasse succeeds David Shaw, who has served as chairman and interim CEO since the creation of Ikaria in March 2007 and will now serve as executive chairman